| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: Help Conquer Cancer
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 954
|
|
| Author |
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Threshold Pharmaceuticals Presents Interim Pr...ly Stage Trials of TH-302
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 15 to 19, 2009, in Boston, MA. "Prostate cancer is known to be hypoxic. Several years ago we furthered the support for the rationale of using TH-302 to treat prostate cancer when TH-302 was combined with docetaxel in a preclinical metastatic model of prostate cancer and eradicated all signs of disease," said Charles P. Hart, Ph.D., Threshold's vice president of Biology. "This week we have summarized both the benchwork data and initial clinical data. We are excited to continue investigations with TH-302 and with the potential benefit that it might confer to people living with prostate cancer." The presentation summarized a series of translational models and select results from two clinical trials of TH-302. Results from these clinical trials were previously discussed at various medical meetings this year. The two clinical trials are both evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors; one in combination with other chemotherapy agents (the 402 trial) and the other with TH-302 as monotherapy (the 401 trial). In this presentation, results from patients with metastatic castration-resistant prostate cancer (CRPC) were discussed. Results from 14 patients with metastatic CRPC from the two clinical trials were presented in a poster entitled "Bench to Bedside Experience with TH-302: a Tumor-Selective Hypoxia-Activated Prodrug as a Promising Treatment for Prostate Cancer." Clinical Trial Results; ....... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Australian scientists are behind a major brea...cancer cells proliferate.
Australian scientists are behind a major breakthrough in detecting the mechanisms that make cancer cells proliferate. Cancer cells, unlike normal cells, have the ability to be 'immortal' so to speak, to continue reproducing and so to form tumours. They do this using two mechanisms. The first is telomerase, discovered by Elizabeth Blackburn in 1985, for which she was awarded the Nobel prize just a few weeks ago. The second, the use of something known as ALT or 'alternative lengthening of telomeres' which was discovered in 1995 by Professor Roger Reddel, the director of the Children's Medical Research Institute in Sydney. 23 November 2009 |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Centre pioneers robotic surgery
Surgeons control robotic arms which are capable of great precision A £2m device which carries out robotic surgery is being pioneered in Oxford. The duel-console gadget, which is the only one of its kind in the UK, is used by surgeons to carry out precise keyhole surgery. Its unique design allows surgeons to train others more quickly and safer than ever before, the Oxford Cancer Centre said. It will be used in some prostate and renal cancer operations, with surgeons aiming to expand its use in the future. A set of robotic arms, operated by the surgeon sitting at a console, is used to carry out invasive surgery with great precision, the university said...... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Tiny magnetic discs could kill cancer cells: study
Tiny magnetic discs just a millionth of a metre in diameter could be used to used to kill cancer cells, according to a study published on Sunday. Laboratory tests found the so-called "nanodiscs", around 60 billionths of a metre thick, could be used to disrupt the membranes of cancer cells, causing them to self-destruct.... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Realmente interesantes noticias acerca de la Lucha contra el cancer.-Creo que la batalla final se dara cuando sepamos completamente lo relacionado con genoma y proteoma en su totalidad, por ello es Importante la tarea que cumple esta comunidad.-felicitaciones.-Conocimiento del cosmo global .-
----------------------------------------[Edit 1 times, last edit by Former Member at Dec 3, 2009 1:16:00 AM] |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Hola Luis , un gusto en verte nuevamente
 Saludos desde Santiago ! JP |
||
|
|
Somervillejudson@netscape.net
Veteran Cruncher USA Joined: May 16, 2008 Post Count: 1065 Status: Offline Project Badges: 
|
Wonder if exposure to a continuous strong magnetic feild could protect one from cancer? Doubt there would be any significant negative side effects, that is as long as one nailed down all the objects cotaining Iron in ones home!
|
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Combining nanotubes and antibodies for breast...and destroy' missions
Single-walled nanotubes cylinders of carbon about a nanometer in diameter have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells. Thanks to a new development by researchers at the National Institute of Standards and Technology (NIST) and five partners, you can add one more application to the list: detection and destruction of an aggressive form of breast cancer. HER2 is one of a family of genes that help regulate the growth and proliferation of human cells. Normal cells have two copies of HER2, but about 20 to 25 percent of breast cancer cells have multiple copies of the gene, resulting in the overproduction of a HER2-encoded protein (called HER2 and designated in Roman type versus italics for the gene) that is associated with particularly fast growing and difficult to treat tumors. About 40,000 women in the United States are diagnosed annually with this form of breast cancer..... |
||
|
|
[C@B] ljfc2001
Cruncher Joined: Jul 21, 2006 Post Count: 17 Status: Offline Project Badges: 
|
Gracias Jean Pierre por mantenernos informados.
----------------------------------------This month we wait to advance in this project. Un saludo desde España.  [Edit 1 times, last edit by [C@B] ljfc2001 at Dec 9, 2009 1:05:58 AM] |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Hola
, de nada , un cordial saludo desde aqui a la quierida España , escribeme cuando quieras o necesites algo Scientists Develop 20-Minute Nanosensor for Whole Blood-Based Biomarker Identification. Scientists report developing a nanosensor-based technology that allowed the detection of picogram-per-milliliter concentrations of a cancer biomarker in whole blood in 20 minutes. They suggest that the new technology, which may be used in other biological fluids, not only represents the first time nanosensors have been used to detect biomarkers in complex fluids but that it could also change the way clinicians test for disease-related biomarkers both in an office setting and potentially in the field. The developments are reported in Nature Nanotechnology in a paper titled “Label-free biomarker detection from whole blood.” .. |
||
|
|
|